Skip to content
Berzosertib
Berzosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase ATR. In addition, it is known to target serine/threonine-protein kinase mTOR, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, and serine-protein kinase ATM.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8083———9
Small cell lung carcinomaD05575233———5
Ovarian neoplasmsD010051EFO_0003893C5632———4
Lung neoplasmsD008175C34.9031———3
Non-small-cell lung carcinomaD00228921———2
LeiomyosarcomaD007890—2———2
Fallopian tube neoplasmsD00518511———2
Prostatic neoplasmsD011471C61—1———1
Castration-resistant prostatic neoplasmsD064129—1———1
Stomach neoplasmsD013274EFO_0003897C16—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell neoplasmsD0183071————1
Colorectal neoplasmsD0151791————1
Pancreatic neoplasmsD010190EFO_0003860C251————1
Breast neoplasmsD001943EFO_0003869C501————1
Triple negative breast neoplasmsD0647261————1
Squamous cell carcinoma of head and neckD0000771951————1
Squamous cell carcinomaD0022941————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBERZOSERTIB
INNberzosertib
Description
3-[3-[4-(methylaminomethyl)phenyl]-5-isoxazolyl]-5-(4-propan-2-ylsulfonylphenyl)-2-pyrazinamine is a sulfonamide.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CNCc1ccc(-c2cc(-c3nc(-c4ccc(S(=O)(=O)C(C)C)cc4)cnc3N)on2)cc1
Identifiers
PDB—
CAS-ID1232416-25-9
RxCUI—
ChEMBL IDCHEMBL3989870
ChEBI ID—
PubChem CID59472121
DrugBankDB11794
UNII IDL423PRV3V3 (ChemIDplus, GSRS)
Target
Agency Approved
ATR
ATR
Organism
Homo sapiens
Gene name
ATR
Gene synonyms
FRP1
NCBI Gene ID
545
Protein name
serine/threonine-protein kinase ATR
Protein synonyms
Ataxia telangiectasia and Rad3-related protein, FRAP-related protein 1, FRAP-related protein-1, MEC1, mitosis entry checkpoint 1, homolog
Uniprot ID
Q9BXK4
Mouse ortholog
Atr (245000)
serine/threonine-protein kinase ATR (Q9JKK8)
Alternate
MTOR
MTOR
PIK3CG
PIK3CG
ATM
ATM
Organism
Homo sapiens
Gene name
MTOR
Gene synonyms
FRAP, FRAP1, FRAP2, RAFT1, RAPT1
NCBI Gene ID
2475
Protein name
serine/threonine-protein kinase mTOR
Protein synonyms
FK506 binding protein 12-rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP-rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, Mammalian target of rapamycin, Mechanistic target of rapamycin, mechanistic target of rapamycin (serine/threonine kinase), mTOR, Rapamycin and FKBP12 target 1, rapamycin associated protein FRAP2, Rapamycin target protein 1
Uniprot ID
Q9Y4I3
Mouse ortholog
Mtor (56717)
serine/threonine-protein kinase mTOR (Q9JLN9)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 276 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
34 adverse events reported
View more details